Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

253 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Discovery of a potent boronic acid derived inhibitor of the HCV RNA-dependent RNA polymerase.
Maynard A, Crosby RM, Ellis B, Hamatake R, Hong Z, Johns BA, Kahler KM, Koble C, Leivers A, Leivers MR, Mathis A, Peat AJ, Pouliot JJ, Roberts CD, Samano V, Schmidt RM, Smith GK, Spaltenstein A, Stewart EL, Thommes P, Turner EM, Voitenleitner C, Walker JT, Waitt G, Weatherhead J, Weaver K, Williams S, Wright L, Xiong ZZ, Haigh D, Shotwell JB. Maynard A, et al. Among authors: walker jt. J Med Chem. 2014 Mar 13;57(5):1902-13. doi: 10.1021/jm400317w. Epub 2013 May 29. J Med Chem. 2014. PMID: 23672667
In vitro characterization of GSK2485852, a novel hepatitis C virus polymerase inhibitor.
Voitenleitner C, Crosby R, Walker J, Remlinger K, Vamathevan J, Wang A, You S, Johnson J 3rd, Woldu E, Van Horn S, Horton J, Creech K, Shotwell JB, Hong Z, Hamatake R. Voitenleitner C, et al. Antimicrob Agents Chemother. 2013 Nov;57(11):5216-24. doi: 10.1128/AAC.00874-13. Epub 2013 Aug 12. Antimicrob Agents Chemother. 2013. PMID: 23939896 Free PMC article.
A double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis C virus genotype 1-infected treatment-naive subjects.
Gardner S, Cutrell A, Elko-Simms C, Adkison K, Hamatake R, Walker J, Rodriguez-Torres M, Hong Z. Gardner S, et al. Liver Int. 2014 Jul;34(6):e89-95. doi: 10.1111/liv.12334. Epub 2013 Oct 16. Liver Int. 2014. PMID: 24107072 Clinical Trial.
A randomized, double blind, dose escalation, first time in human study to assess the safety, tolerability, pharmacokinetics, and antiviral activity of single doses of GSK2485852 in chronically infected hepatitis C subjects.
Wilfret DA, Walker J, Voitenleitner C, Baptiste-Brown S, Lovern M, Kim J, Adkison K, Shotwell B, Mathis A, Moss L, Lee D, Yu L, Gan J, Spaltenstein A. Wilfret DA, et al. Clin Pharmacol Drug Dev. 2014 Nov;3(6):439-48. doi: 10.1002/cpdd.142. Epub 2014 Oct 20. Clin Pharmacol Drug Dev. 2014. PMID: 27129119 Clinical Trial.
253 results